5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients with Low and Intermediate Risk Prostate Cancer.

Michael J Zelefsky,Marisa Kollmeier,Sean McBride,Melissa Varghese,Borys Mychalczak,Richard Gewanter,Madhur K Garg,Laura Happersett,Debra A Goldman,Isaac Pei,Mary Lin,Zhigang Zhang,Brett W Cox

International Journal of Radiation Oncology*Biology*Physics（2019）

引用 81|浏览58

暂无评分

摘要

SBRT doses ranging from 32.5 Gy-40 Gy in 5 fractions were well tolerated without severe urinary or rectal toxicities. Biopsy outcomes suggest improved rates of tumor clearance observed with higher doses.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要